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Background: This study aimed to assess the impact of leak compensation capabilities during
pressure- and volume-limited non-invasive positive-pressure ventilation (NPPV) in COPD
patients.
Methods: Fourteen patients with stable hypercapnic COPD who were receiving long-term NPPV
were included in the study. For both modes of NPPV, a full face mask and an artificial leak in
the ventilatory circuit were used at three different settings, and applied during daytime NPPV,
either without leakage (setting I), with leakage during inspiration only (setting II), and with
leakage during inspiration and expiration (setting III). Ventilation pattern was pneumotachy-
graphically recorded.
Results: NPPV was feasible with negligible leak volumes, indicating optimal mask fitting during
the daytime (setting I). In the presence of leakage (settings II and III), the attempt to compen-
sate for leak was only evident during pressure-limited NPPV, since inspiratory volumes deliv-
ered by the ventilator increased from 726 129 (setting I) to 1104 164 (setting II), and to
1257 166 (setting III) ml during pressure-limited NPPV, respectively (all p< 0.001); however,
they remained stable during volume-limited NPPV. Leak compensation resulted in a decrease
in leakage-induced dyspnea. However, 83%/87% (setting II/III) of the additionally-deliveredriance; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CO2, carbon dioxide;
FVC, forced vital capacity; fb, breathing frequency; HCO3
, standard bicarbonate; HRF, hypercapnic
r; IPAP, inspiratory positive airway pressure; LTOT, long-term oxygen therapy; ml, milliliter; mm,
on-invasive positive-pressure ventilation; PEEP, positive end expiratory pressure; PCV, pressure
l partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; PIP, peak inspiratory
ressures; ref, reference; RV, residual volume; SaO2, oxygen saturation; SD, standard deviation; TLC,
volumes; V-insp, inspiratory volumes; V-leak, leakage volumes; VCV, volume controlled ventilation.
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1478 J.H. Storre et al.inspiratory volume during pressure-limited NPPV was also lost via leakage. Expiratory volume
was higher in setting II compared to setting III (both p< 0.001), indicating the presence of
significant expiratory leakage.
Conclusions: The attempt at leak compensation largely feeds the leakage itself and only
results in a marginal increase of tidal volume. However, pressure-limited e but not volume-
limited e NPPV results in a clinically-important leak compensation in vivo. Trial registration:
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html Identifier: UKF001272.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Non-invasive positive-pressure ventilation (NPPV) using
a face mask has become an important means to treat
patients with hypercapnic respiratory failure (HRF) arising
from different aetiologies including restrictive thoracic
diseases, neuromuscular disorders, obesity hypoventilation
syndrome and chronic obstructive pulmonary disease
(COPD).1e7 However, one major problem with the applica-
tion of long-term NPPV is the occurrence of leakage via
a poorly-fitting mask or an open mouth. This can potentially
lead to considerable impairment of ventilation quality.8e12
In addition, leakage is suggested to be one of the major
factors that lead to side effects such as conjunctivitis and
impaired sleep quality.4,9,10 Therefore, avoiding leakage, or
at least keeping it to a minimum, is of major clinical
importance for the application of NPPV.
In general, there exist two primary modes for controlling
NPPV tidal volumes: pressure-limited NPPV and volume-
limited NPPV. During pressure-limited NPPV the inspiratory
pressure is set, while the inspiratory volumes (V-insp)
delivered by the ventilator vary according to the resistance
of the respiratory system. In contrast, during volume-
limited NPPV, a predetermined V-insp is set, while inspi-
ratory pressures are variable. One theoretical but impor-
tant difference between volume- and pressure-limited
NPPV is leak compensation. While leak compensation is
proposed not to occur during volume-limited NPPV, inspi-
ratory flow is increased during pressure-limited NPPV in the
presence of leakage in order to reach the inspiratory
pressure set.4 Interestingly, one in vitro study shows that
these theoretical considerations are valid for the settings of
a laboratory study.13
However, the relative leak compensation capabilities of
pressure- versus volume-limited NPPV have not yet been
tested in vivo. Moreover, it remains unclear whether the
additionally-delivered V-insp, which aims to compensate
for leakage, actually does increase tidal volume, or
whether in reality simply feeds the leakage and therefore
increases the leak volume. This is conceivable given the
fact that leak compensation does not diminish the leakage
per se. As a consequence, the clinical impact of the relative
leak compensation capabilities of each NPPV mode remains
unclear. For this reason, the present study aimed to
compare leak compensation capabilities and their respec-
tive clinical impacts during pressure- and volume-limited
NPPV in patients with chronic HRF. Thereby, it was
hypothesised, based on the aforementioned in vitro
study,13 that pressure-limited NPPV is superior to volume-limited NPPV, and therefore capable of preventing dyspnea
in the case of leakage.
Material and methods
The study protocol was approved by the Institutional
Review Board for Human Studies at the Albert-Ludwigs
University, Freiburg, Germany, and was performed in
accordance with the ethical standards laid down in the
Declaration of Helsinki. Written informed consent was
obtained from all patients.
Patients
Stable hypercapnic COPD patients (Stage IV according to
GOLD criteria14) established on long-term NPPV for at least
two months were recruited for this study.15 All patients had
been familiar with pressure controlled ventilation (PCV)
when entering the study, and none patient had received
volume controlled ventilation (VCV) at home. Measurements
were performed during an admission to hospital for a routine
control check of NPPV. These control checks are generally
performed two times in the first year and annually for the
subsequent years following the commencement of long-term
NPPV in order to control quality of ventilation and adherence
to therapy. Patients with evidence of acute respiratory
failure (e.g. worsening symptoms during the last two weeks,
a breathing frequency (fb)> 30/min, a pH< 7.35, or signs of
respiratory infections) were excluded.
Study design
Pressure-limited (PCV) and volume-limited (VCV) NPPV in the
assist/control mode were performed using the PV403 venti-
lator (BREAS Medical AB; Mo¨lnlycke, Sweden). An oronasal
mask (Mirage Full Face Mask; Series 2 Medium mask, ResMed
Ltd; North Ryde, Australia) without exhalation holes was
used to prevent mouth leakage in all patients with a dead
space of 200 ml according to manufacture’s declarations.
Experimental set-up is shown in Fig. 1. A short tube
(55 mm) with an adapter open to the atmosphere (ID 4 mm;
Oxygen Adapter No. 1974; BþP Beatmungsprodukte GmbH;
Neunkirchen-Seelscheid, Germany) was used to simulate
the leakage, and was placed between the exhalation port
and the distal end of the mask by using a T-connector (REF
60e11-503, VBM Medizintechnik GmbH; Sulz a.N.,
Germany), as shown in Fig. 1. Dead space of the tube and
the T-connector was measured to be 25 ml.
Table 1 Patient characteristics (including blood gases)
during daytime without supplemental oxygen and without
NPPV (NZ 14).
Mean SD
Age (years) 67.6 9.0
BMI (kg/m2) 27.5 6.7
Clinical impact of leak compensation in NIV 1479All measurements were performed during daytime NPPV.
Patients were not randomized and not blinded to receive
either PCV or VCV for methodological reason outlined below.
However, measurements for each mode (PCV and VCV) were
randomly performed and blinded to the patient. Thereby
three different settings have been performed for each
mode, respectively: (I) without leakage; (II) inspiratory
leakage; (III) inspiratory and expiratory leakage. At setting I,
the adapter of the short tube was locked by a Combi-Stopper
(Ref. 4495152; B.BRAUN; Melsungen, Germany). In contrast,
the adapter was not locked at all during setting III (inspira-
tory and expiratory leakage). At setting II, the adapter was
manually locked with the investigator’s thumb during expi-
ration only (inspiratory leakage). Initially, NPPV was used
with implementation of PCV for all three settings, and this
was followed by VCV for all three settings, respectively. In
total, six different measurements of 20 min periods were
performed in each patient.
For PCV, the same settings as those used at home were
chosen. Tidal volume settings for VCV were obtained from
pneumotachygraphic measurements of V-insp, while PCV
was performed without leakage (setting I). Therefore, ran-
domisation of patients to receive either PCV or VCV was not
performed. Respiratory rate and inspiratory time were not
changed during the study protocol. No positive end expira-
tory pressure (PEEP) was used to minimize expiratory
leakage.Oxygen supplywas providedwith the sameflow rate
as that used at home and was not changed during the study.
Measurements
Lung function parameters (Masterlab-Compact Labor,
Jaeger, Germany) were measured at baseline. Daytime
blood gases were taken at rest from the arterialized earlobe
(AVL OMNI; Roche Diagnostics GmbH; Graz, Austria).
Ventilation pattern was recorded using a pneumotachy-
graph (Ventrak-Respiratory-Monitoring-System; Model
1550; Novametrix Medical System Inc., USA, dead space
6.5 ml) placed between the exhalation port tubing (dead
space 7 ml) and the distal end of the mask (Fig. 1). Volumes
for inspiration (V-insp), expiration (V-exp), leakage
(V-leak), peak inspiratory pressures (PIP), mean inspiratory
pressures (Pmean) and breathing frequencies (fb) were
continuously recorded. After 20 min of each setting oxygenFigure 1 Experimental set-up during PCV and VCV. Detailed
description is provided in Material and Method section.saturation (SaO2) was measured (NPB-40, Nellcor Puritan
Bennett, Pleasanton, CA 94588, Ireland). At the conclusion
of each setting patients were asked to rate their dyspnea
using a visual analogue scale from 1 (minimal) to 5
(maximal).
Statistical analysis
Statistical analysis was performed using Sigma-Stat
(Version 3.1, Systat Software, Inc.; Point Richmond, Cal-
ifornia, USA). Data are presented as mean SD after
testing for normal distribution (KolmogoroveSmirnov Test).
One Way Repeated Measures Analysis of Variance (ANOVA)
was performed to compare measurements at setting I,
setting II and setting III; here, pairwise multiple compari-
sons were performed using the HolmeSidak method.
Comparisons between measurements at two different time
points were performed using the paired t-test on normally
distributed data, or the Wilcoxon signed rank test on non-
normally distributed data. Statistical significance was
assumed with a p-value 0.05.
Results
Fourteen patients with severe COPD completed the study.
The characteristics of patients are given in Table 1. In PCV
an inspiratory airway pressure (IPAP) of 31.6 4.4 mbar was
used. For VCV the tidal volume was set to 715 123 ml. For
both PCV and VCV, the settings for breathing frequency
(21.1 2.1/min), inspiratory time (34.5 3.5 %), inspira-
tory trigger (0.2 0.1 mbar), PEEP (0.0 0.0 mbar) and
supplemental oxygen (2.0 0.8 l/min) were identical.
Pneumotachygraphic measurements and sense of dyspnea
reported by the patients are presented in Table 2. A typical
example of finding is shown in Fig. 2.Use of NPPV (month) 40.7 32.9
LTOT (L/min) 1.7 1.1
FEV1 (% predicted) 27.1 10.0
FVC (% predicted) 49.9 10.2
FEV1/FVC (%) 46.4 11.5
RV (% predicted) 266.7 67.6
TLC (% predicted) 120.6 22.9
pHa 7.41 0.03
PaCO2 (mmHg)
a 46.0 4.4
PaO2 (mmHg)
a 56.9 6.8
HCO3 (mmol/l)
a 28.1 3.1
BMIZ body mass index, FEV1Z forced expiratory volume in 1 s,
FVCZ forced vital capacity, HCO3 Z standard bicarbonate,
LTOTZ long-term oxygen therapy, PaCO2Z arterial partial
pressure of carbon dioxide, PaO2Z arterial partial pressure of
oxygen, RVZ residual volume, TLCZ total lung capacity. Lung
function parameters are given in %predicted.16
a NZ 9.
Table 2 Pneumotachygraphic measurements, oxygen saturation and sense of dyspnea during VCV and PCV. Values are given in
mean SD.
V-insp
(ml)
V-exp
(ml)
V-leak
(ml)
Pmean
(mbar)
PIP
(mbar)
fb
(/min)
SaO2 after
20 min (%)
Dyspnea
(1Zmin,
5Zmax)
Setting I
PCV e without leakage 726 129 711 120 28 38 8.8 1.5 28.6 3.8 21.4 2.3 97 2 1.3 0.5
VCV e without leakage 755 137 734 129 30 49 9.2 2.2 28.3 6.2 21.1 2.0 98 1 1.6 0.5
p-Value 0.006 n.s. n.s. n.s. n.s. 0.027 n.s. n.s.
Setting II
PCV e inspiratory leakage only 1104 164 591 110 513 79 6.6 1.3 22.7 3.5 21.5 2.3 97 1 1.3 0.5
VCV e inspiratory leakage only 776 144 525 91 251 111 3.2 1.1 13.0 3.4 21.5 2.2 97 2 2.9 1.0
p-Value <0.001 0.002 <0.001 <0.001 <0.001 n.s. n.s. <0.001
Setting III
PCV e inspþ exp
leakage
1257 166 372 119 885 94 5.5 1.1 20.3 3.0 21.3 2.1 97 2 1.3 0.5
VCVe inspþ exp
leakage
793 138 302 97 491 120 2.4 1.0 11.2 4.4 22.2 2.9 96 2 3.1 0.9
p-Value <0.001 <0.001 <0.001 <0.001 <0.001 n.s. 0.04 <0.001
fbZ breathing frequency, PCVZ pressure controlled ventilation, PIPZ peak inspiratory pressure, PmeanZmean inspiratory and
expiratory pressure, SaO2Z oxygen saturation, V-expZ expiratory volume, V-inspZ inspiratory volume, V-leak Z leakage volume,
calculated by the difference of V-insp and V-exp, VCVZ volume controlled ventilation. Setting I: without leakage; setting II: inspiratory
leakage; setting III: inspiratory and expiratory leakage, insp Z inspiratory, exp Z expiratory.
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were comparable, with the exception of a slightly higher V-
insp and lower fb during VCV. In addition, V-leak was
negligible, indicating optimal mask fitting. At settings II and
III, significant V-leak was recorded, resulting in reduced V-
exp (all p< 0.001). However, leak compensation was only
evident during PCV, since V-insp increased from 726 129
(setting I) to 1104 164 (setting II), and to 1257 166
(setting III) ml during PCV, respectively (all p< 0.001). In
contrast, V-insp did not change significantly during VCV. In
addition, Pmean and PIP were considerably lower during
VCV compared to PCV at settings II and III, indicating
differences in leak compensation (Table 2). Interestingly,
leak compensation during PCV resulted in less dyspnea
compared to VCV. Moreover, V-exp at setting III was lower
(all p< 0.001) and V-leak higher (all p< 0.001) than the
equivalent recordings at setting II, indicating substantial
leakage during expiration (Table 2). Importantly, addition-
ally-delivered V-insp during leakage (settings II and III) led
to a small but significant increase in V-exp, while most of
the additionally-delivered V-insp fed the V-leak (Table 2).
Here, 17 (13)% and 83 (87)% of the additionally-delivered
volume accounted for V-exp and V-leak, respectively, at
setting II (III).Discussion
This is the first in vivo study to quantify and compare the
leak compensation capabilities of PCV and VCV during
NPPV. Four major findings arise out of this work.
Firstly, leak volume is negligible when optimal mask
fitting is achieved, and leak compensation is neither
evident nor necessary during either PCV or VCV. Thus itappears both modes are comparable with regard to
handling of minor leakage when mask fitting is optimal.
Secondly, in the event of leakage, the delivered
volume is increased during PCV, but not VCV. In addition,
the mean and peak inspiratory pressures are higher during
PCV compared to VCV. This clearly shows that leak
compensation occurs in vivo during PCV only, strongly
supporting previous in vitro findings.13 Importantly,
dyspnea increases when leakage is evident, but only when
leak compensation fails to occur during VCV. This is novel
and convincing evidence for the potential clinical
importance of the leak compensation capabilities of NPPV
respirators. SaO2 was also found to be reduced with VCV,
but this was only marginal and statistical significant when
inspiratory and expiratory leakage was present. There-
fore, other mechanisms beside SaO2 are suggested to be
responsible for dyspnea in the case of leakage. With this
regard patients might have had more dyspnea with VCV
which has been adjusted for the first time, since all
patients have been familiar only with PCV. Therefore, the
clinical observation of higher levels of dyspnea during
VCV in case of leakage needs further investigation.
However, a trend of higher dyspnea levels in VCV has been
reported previously, although this was statistical not
significant.11 Rebreathing of CO2, which has not been
quantified in the presence study, could have theoretically
effected dyspnea sensation considering the need for extra
tubing systems for the purpose of the study. However,
tubing maximally accounted for 38.5 ml dead space and
this is suggested not to have substantially influenced
rebreathing.
Thirdly, this study shows that the delivery of additional
volume during inspiration e which is aimed to compensate
for leakage during PCV e largely feeds the leakage and only
Figure 2 Example curves of a 54-year old patient with COPD. Volumes for inspiration (V-insp) and expiration (V-exp) are shown in
Panel AeC for PCV and in Panel EeG for VCV. Mean values are given for every minute. Panels D (PCV) and H (VCV) illustrate V-exp
during both settings implementing artificial leakage (settings II and III): white boxes represent V-exp during PCV or VCV with
inspiratory leakage only (setting II); grey boxes represent V-exp during PCV or VCV with inspiratory and expiratory leakage (setting
III), respectively. In Panels D and H mean and 95% confidence interval are shown. For further explanation see Material and Method
section.
Clinical impact of leak compensation in NIV 1481marginally increases tidal volume, as estimated from the
expiratory volume in the present study and also proposed in
previous findings.11,17 Given the above-mentioned clinical
benefits of leak compensation, this marginal but statistically
significant increase in tidal volume is suggested to be clini-
cally relevant. Nevertheless, the marked increase in inspi-
ratory volume, which, in fact, exacerbates the leakage,
could also cause side effects such as mouth and throat
dryness, eye conjunctivitis or sleep disturbances; the like-
lihood of such side effects occurring is increased by the fact
that long-term NPPV is predominantly applied during night,
where leakage is reportedly substantial.9e12,17e21 Impor-
tantly, randomized controlled trials comparing nocturnal
PCV to VCV revealed no differences in the clinical outcome
of overnight NPPV,11,17 although higher levels of side effects
have been reported on VCV in one trial.11 Therefore, PCV is
clearly advantageous in terms of leak compensation, both in
vivo, as shown in the present study, and in vitro13; however,
since the compensated volume only marginally accounts for
an increase in tidal volume, the clinical advantage of leak
compensation still remains unclear. Furthermore, leak
compensation of PCV was incomplete, since PCV was not
able to completely maintain the PIP during leakage.
However, previous work has shown that the ability to
compensate for leakage is also depending on the devise
being used.13 Only one device was used in the present study,therefore differences in leak compensation capabilities of
different ventilators could not be excluded.
Fourthly, leak volume, as estimated from the difference
of inspiratory and expiratory volumes, occurs during both
inspiration and expiration. In the past, tidal volume has
been estimated from the expiratory volume.8,11,12,17
However, given the observation that volume is also lost
during expiration, tidal volume could be underestimated
from expiratory volume, and, as a consequence, crucial
leak volume (inspiratory leakage) might be overestimated.
The present study has some noteworthy limitations:
Firstly, only daytime measurements were performed;
therefore, the results cannot be directly applied to
nocturnal NPPV. Secondly, patients were familiar with PCV,
but not VCV, which could have influenced the sense of
dyspnea. Thirdly, patients were not blinded and not
randomized to receive PCV and VCV, and this might also
have affected dyspnea sensation. The reason for this was
the adoption of pneumotachygraphically measured V-insp
during PCV for setting the volume being delivered during
inspiration while on VCV. However, subsequent measure-
ments for each mode (PCV and VCV) were randomly
performed and blinded to the patient. Fourthly, leakage
was somewhat artificial, since there was no difference in
the simulation of inspiratory and expiratory leakage.
However, under real physiological conditions, inspiratory
1482 J.H. Storre et al.and expiratory leakage could differ considerably, depend-
ing on lip closure or the varying position of the soft palate.8
Fifthly, side effects during NPPV with and without leakage
have not been addressed. Less gastrointestinal side effects
have previously been reported in favour of overnight PCV
compared to VCV.11 However, this does not predict daytime
application of NPPV and the degree of airflow as influenced
by leakage might have led to more aerophagia, which has
not been addressed in the present study. Finally, the
manual exclusion of expiratory leakage in order to generate
just inspiratory leakage could be associated with some
degree of inaccuracy, although this is likely to be marginal,
given the clear differences in measurements between
inspiratory and expiratory leakage. Nevertheless, despite
these limitations, the present study clearly shows in vivo
differences in the performance of PCV and VCV used to
provide NPPV.
In conclusion, this in vivo study shows that leak
compensation during daytime NPPV is present during pres-
sure-limited NPPV, but not volume-limited NPPV. Leak
compensation has been shown to reduce dyspnea in the
case of leakage, although the additionally-delivered inspi-
ratory volume mostly feeds the leakage and only marginally
increases tidal volume. Additional studies examining
nocturnal NPPV are needed for a more precise estimation of
the clinical impact of leak compensation provided by
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